The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

NCT04356872 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG: Sintilimab
DRUG: Doxorubicin Hydrochloride
DRUG: Ifosfamide

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]